The Boston-based neurological disease treatment company develops the eShunt system for treating communicating hydrocephalus. In a news release, it said Malek’s appointment can help further accelerate the development and clinical strategy for eShunt.
Current treatment for hydrocephalus requires an invasive neurosurgical procedure, CereVasc says. The company designed its minimally invasive eShunt with an endovascularly implantable CSF count and associated delivery components. These help to avoid the need for invasive surgery, general anesthesia, extended hospitalization and post-procedure pain management. Malek is a co-inventor of the eShunt.
“We are thrilled to welcome Dr. Malek to the leadership team at CereVasc,” said Dan Levangie, CereVasc chair and CEO. “With his vast experience, innovative thinking and focus on patient care, Dr. Malek is well suited to guide the medical strategy for CereVasc as we expand our clinical and product development programs.”
More about new CereVasc CMO Dr. Adel Malek
Malek joins CereVasc as the chief of neurovascular surgery and director of the cerebrovascular and endovascular division in the department of Neurosurgery at Tufts Medical Center. He also serves as a professor of neurosurgery at Tufts University School of Medicine.
The Boston-based, board-certified neurosurgeon specializes in treating brain aneurysms, arteriovenous malformations and stroke. He has dual training in microsurgery and minimally invasive endovascular neurosurgery.
“I am excited about the opportunity to contribute to the great pioneering innovations at CereVasc as we embark on expanded clinical studies and product development initiatives,” Malek said. “Having worked with the team for the past eight years, I have been impressed with the passion for improving patient care and dedication to transformative innovation and am looking forward to supporting this important mission.”